Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Frederick, MD, US. The stock last traded at $8.63, up 0.52% on the session, giving a market capitalisation of $253.6M. On trailing twelve-month figures it carries a trailing P/E of -1.46, a net margin of -10422.5%. Its beta of 0.56 implies it has historically moved less than the broad market.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Cartesian Therapeutics, Inc. is most often compared with the following Healthcare names: